Telmisartan

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Telmisartan

Examples of brand names: Micardis [EU/DE]

ATC code: C09CA07

Main use (for orientation): Hypertension

Documented research summary

Direct combinations of CBD or CBG with telmisartan were investigated in murine BV2 microglial cells (PMID 38003444 and 36830745). NO endpoints, not clinical pharmacokinetics or confirmation of efficacy. Receptor-crosstalk reviews alone provide no measured pharmacokinetic interaction. Additional non-inventoried literature lead concerning captopril: see VD_SUPP001; not a complete individual captopril review or a master pair finding.

Uncertainties and limitations

Missing data do not establish safety. Research is limited by the documented sources, search terms, languages and accessibility.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0428

Type of result: Preclinical endpoint

Observation: CBD/telmisartan together reduced NO by 95%, compared with 60% for telmisartan and 37% for CBD; the authors interpret this as additive.

Mechanism: Pharmacodynamic modulation of LPS-induced NO production in BV2 cells.

Study type: Original in vitro study

Context studied: 5 µM each; LPS 7 ng/ml; 24 hours; three independent experiments, n=12 measurements.

Clinical interpretation: Clinical significance unresolved

Limitations and uncertainties: No measured clinical interaction, blood-pressure effect or treatment recommendation; cell concentrations cannot be transferred as doses.

Original sources for this finding: An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release. [RMED38003444]

CBG – laboratory and animal studies

Finding ID: B0429

Type of result: Preclinical endpoint

Observation: The combination reduced NO additively; telmisartan and CBG alone reduced the LPS effect by 17% and 29%, respectively.

Mechanism: Pharmacodynamic modulation of NO production in the LPS-activated microglial cell model.

Study type: Original in vitro study

Context studied: BV2 cells; CBG 5 µM, telmisartan 5 µM, LPS 7 ng/ml; 22 hours. Two to three independent experiments; n=6 according to the figure.

Clinical interpretation: Clinical significance unresolved

Limitations and uncertainties: The additionally reported EAE animal experiment assessed CBG alone, not the combination. No clinical efficacy or pharmacokinetic evidence.

Original sources for this finding: Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo. [VD_MED_36830745]

References and access status

[VD_LABEL_D0220] TELMISARTAN TABLET [PREFERRED PHARMACEUTICALS INC.] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[RMED38003444] An Emerging Strategy for Neuroinflammation Treatment: Combined Cannabidiol and Angiotensin Receptor Blockers Treatments Effectively Inhibit Glial Nitric Oxide Release.

Original source / bibliographic reference

Authors: Fleisher-Berkovich S, Battaglia V, Baratta F, Brusa P, Ventura Y, Sharon N, Dahan A, Collino M, Ben-Shabat S.

Year: 2023

Source type: Original publication; see finding for study type

DOI: 10.3390/ijms242216254

PMID: 38003444

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[VD_MED_36830745] Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo.

Original source / bibliographic reference

Authors: Fleisher-Berkovich S, Ventura Y, Amoyal M, Dahan A, Feinshtein V, Alfahel L, Israelson A, Bernstein N, Gorelick J, Ben-Shabat S.

Year: 2023

Source type: Research Support, Non-U.S. Gov't; research-article; Journal Article

DOI: 10.3390/biom13020376

PMID: 36830745

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility